Literature DB >> 3513293

Acid secretory tests in peptic ulcer disease before and after parietal cell vagotomy.

H Graffner, G Liedberg, J Oscarson.   

Abstract

The aim of the present study was to evaluate the role of gastric acid secretory tests in predicting ulcer recurrence in a consecutive series of patients before and up to 5 years after parietal cell vagotomy (PCV). Included in the study are 405 patients with prepyloric or duodenal ulcer disease (57 recurrences). There were no differences in acid secretion in the group of patients with pyloric or prepyloric ulcer disease, with or without recurrences. Thus pre- and post-operative acid secretory tests are of no value in predicting the outcome of PCV in this group of patients. In the duodenal ulcer group both postoperative basal acid output and peak acid output after pentagastrin and after insulin were higher in patients with recurrences. The two best discriminatory values were the ratio between the preoperative and the 6-week value of basal acid output and the 6-week value of peak acid output after insulin. The results of the study suggests that the ratio of the basal output before surgery and 6 weeks after surgery is enough for judging the acid reduction after PCV and that only in the case of a recurrence should an acid stimulation test be used.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513293     DOI: 10.3109/00365528609034619

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  3 in total

1.  Canine gastric muscarinic receptors up-regulate after vagotomy.

Authors:  A Keshavarzian; T B Steck; D Conway; J H Gordon; J Z Fields
Journal:  Dig Dis Sci       Date:  1990-04       Impact factor: 3.199

2.  Increased ulcer relapse rate after PCV in smokers.

Authors:  H Graffner; G Lindell
Journal:  World J Surg       Date:  1988-04       Impact factor: 3.352

Review 3.  Current status of proximal gastric vagotomy.

Authors:  B D Schirmer
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.